Essential Pharma Announces the Acquisition of Reminyl (galantamine hydrobromide) Oral Capsules

Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically differentiated, niche pharmaceutical products across key therapeutic areas, announces that it has completed the acquisition of Reminyl oral capsules from Janssen Pharmaceutica NV, a Johnson & Johnson company.

Reminyl, a cholinesterase inhibitor, is an established central nervous system (CNS) drug indicated for the treatment of mild to moderately severe dementia of the Alzheimer type. Under the terms of the acquisition, Essential Pharma has acquired rights to Reminyl oral capsules in the EEA, Thailand, South Korea and all other current markets for that product, excluding UK and Ireland, Japan and Latin America.

The acquisition of Reminyl represents further validation of Essential Pharma’s status as a trusted partner in ensuring the sustained supply of essential medicines to patients, healthcare providers and carers. As well as being an important addition to Essential Pharma’s portfolio of specialty CNS medicines, the acquisition further expands the Company’s presence globally, particularly in the APAC region.

Emma Johnson, CEO of Essential Pharma, commented: “Our acquisition of rights to Reminyl in these markets will ensure Alzheimer’s patients and caregivers in those regions have continued access to this vital medicine. The acquisition represents a significant and synergistic addition to our concentrated portfolio of CNS products, further expanding our global presence and solidifying our position as a leading specialty pharma group.”